Kyntra Bio Reports Q2 2026 Results

What Happened Kyntra Bio, Inc. announced its financial results for the quarter ended June 30, 2026 by issuing a press release on August 13, 2026. The company filed Form 8-K to furnish that press release (Exhibit 99.1), which is incorporated by reference into the filing.

Key Details

• Filing date: August 13, 2026 (Form 8-K, Item 2.02).
• Reporting period: quarter ended June 30, 2026.
• Press release furnished as Exhibit 99.1; interactive XBRL cover page included as Exhibit 104.
• Form 8-K signed by David DeLucia, Senior Vice President and Chief Financial Officer.

Why It Matters This 8-K notifies investors that Kyntra Bio has publicly released its quarterly financial results (earnings, revenue and related metrics are in the press release). The filing itself does not reproduce financial figures — investors should review Exhibit 99.1 (the press release) or the company’s investor relations materials/EDGAR posting for detailed revenue, earnings, cash position and any management commentary that could affect the stock.